Dear reader,
The Human Vaccines & Immunotherapeutics Editorial Team would like to wish you a happy and successful year 2018.
We thank all Associate Editors, Editorial Board members and Reviewers for their support and help in maintaining high quality of the journal. We are delighted to announce the Reviewer of the Year Award for 2017, which goes to Dr. Chuanxi Fu of Zhejiang Chinese Medical University (p. 1).
The first issue of this year starts with a Portrait of Dr. James Galen of University of Maryland (p. 11), followed by the Profile of the European and Developing Countries Clinical Trials Partnership (Olesen, p. 14).
The Licensed Vaccines section features a review on T-cell responses to the RTS,S malaria vaccine (Moris, p. 17) and three research reports on cytokine patterns induced by the BCG vaccine (Ponte, p. 28), cost-effectiveness of the Hib vaccine in China (Ning, p. 36), and clinical progress of acellular pertussis and reduced TDaP vaccines in adults (Leroux-Roels, p. 45).
Next, four articles on Novel Vaccines introduce an RSV vaccine formulated in the DepoVax oil-based platform (MacDonald, p. 59), a multiplexed opsonophagocytic killing assay for GBS (Choi, p. 67), sero-epidemiology analysis of Coxsackievirus B5 in Chinese children (Gao, p. 74), and a study of the mechanism of antibody generation S. aureus capsular polysaccharide (Anderson, p. 81).
Four Pneumococcal-related articles report on cost-effectiveness of infant vaccination in Korea (Zhang, p. 85), the burden of childhood community-acquired pneumonia in Southeast Asia (Tan, p. 95) and of infection in children <5 years of age (Ceyhan, p. 106), and beliefs about pneumococcal and influenza vaccines in Turkish healthcare workers (Ciftci, p. 111).
The HPV section includes a report on the low prevalence of infection in young Canadian women following a school-based program (Goggin, p. 118), a review of factors affecting vaccine hesitancy (Santhanes, p. 124), and a study of vaccine acceptability in high-risk Greek men (Hoefer, p. 134).
We are happy to present three Immunotherapy articles: preclinical trials of two MVA-based cancer vaccines in combination with checkpoint inhibitors (Remy-Ziller, p. 140) and of cathelicidin-related antimicrobial peptide in therapy of asthma and intestinal colitis (Li, p. 146), and a commentary on the Bifidobacterium-delivered Wilm's tumor-1 protein vaccine (Shirakawa, p. 159).
The Public Health section features a commentary on ten-year experience with electronic immunization registry in China (Kang, p. 163), a data-mining approach to planning and tracking of childhood vaccination (Bhatti, p. 165), and analysis of adverse event reporting in Ghana (Ankrah, p. 172).
We present a study of maternal vaccination Acceptance and attitudes in England (Vishram, p. 179), cost-effectiveness analysis of universal childhood Rotavirus vaccination in Bangladesh (Sarker, p. 189), a report on the development of a pseudovirus-based assay for detection of HIV-neutralizing antibodies (Chen, p. 199), and a case study of pediatric Meningococcal infection in Turkey (Tanır, p. 209).
We are delighted to publish another Special Focus devoted to the NationalImmunisationConference for Health Care Workers held annually in Manchester, UK, and organized by Drs. David Baxter and Martin Guppy. This feature, which is based on talks presented at the 27th meeting in December 2016, includes a review on risk assessment for Japanese encephalitis vaccination (Turtle, p. 213), commentaries addressing the barriers to vaccine acceptance (MacDonald, p. 218) and adolescent and adult vaccine coverage (Falconer, p. 225), and reviews on the need to continue measles vaccination in the post-eradication era (Cosby, p. 229) and the implication of RSV seasonality for vaccination (Broad, p. 234).
Our monthly News, Policy and Profiles (NP&P) track offers a selection of the latest news in the field of vaccines and immunotherapeutics. In this section we also regularly publish opinion pieces on timely, interesting and controversial topics related to vaccines and immunotherapeutics, profiles of companies and organizations, as well as portraits of distinguished scientists in our field. Please contact Acquisitions Editor Adam Weiss ( adam.c.weiss@taylorandfrancis.com) with your ideas for commentaries, opinion pieces, profiles and portraits. Your suggestions for and contributions to our N&P&P track are always welcome!
Sincerely,
Ronald Ellis, PhD
Editor-in-Chief
Adam Weiss, PhD
Acquisitions Editor